Protein Science, Vol 4, Issue 6 1081-1087, Copyright © 1995 by Cold Spring Harbor Laboratory Press

ARTICLE

Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase

J. N. VARGHESE, V. C. EPA and P. M. COLMAN
Biomolecular Research Institute, Parkville, Victoria 3052, Australia

The three-dimensional X-ray structure of a complex of the potent neuraminidase inhibitor 4-guanidino-Neu5Ac2en and influenza virus neuraminidase (Subtype N9) has been obtained utilizing diffraction data to 1.8 A resolution. The interactions of the inhibitor, solvent water molecules, and the active site residues have been accurately determined. Six water molecules bound in the native structure have been displaced by the inhibitor, and the active site residues show no significant conformational changes on binding. Sialic acid, the natural substrate, binds in a half-chair conformation that is isosteric to the inhibitor. The conformation of the inhibitor in the active site of the X-ray structure concurs with that obtained by theoretical calculations and validates the structure-based design of the inhibitor. Comparison of known high-resolution structures of neuraminidase subtypes N2, N9, and B shows good structural conservation of the active site protein atoms, but the location of the water molecules in the respective active sites is less conserved. In particular, the environment of the 4-guanidino group of the inhibitor is strongly conserved and is the basis for the antiviral action of the inhibitor across all presently known influenza strains. Differences in the solvent structure in the active site may be related to variation in the affinities of inhibitors to different subtypes of neuraminidase.
CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				O. Aruksakunwong, M. Malaisree, P. Decha, P. Sompornpisut, V. Parasuk, S. Pianwanit, and S. Hannongbua On the Lower Susceptibility of Oseltamivir to Influenza Neuraminidase Subtype N1 than Those in N2 and N9 Biophys. J., February 1, 2007; 92(3): 798 - 807. [Abstract] [Full Text] [PDF]

				T. Zurcher, P. J. Yates, J. Daly, A. Sahasrabudhe, M. Walters, L. Dash, M. Tisdale, and J. L. McKimm-Breschkin Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro J. Antimicrob. Chemother., October 1, 2006; 58(4): 723 - 732. [Abstract] [Full Text] [PDF]

				A. Moscona Neuraminidase inhibitors for influenza. N. Engl. J. Med., September 29, 2005; 353(13): 1363 - 1373. [Full Text] [PDF]

				T. Suzuki, T. Takahashi, C.-T. Guo, K. I.-P. J. Hidari, D. Miyamoto, H. Goto, Y. Kawaoka, and Y. Suzuki Sialidase Activity of Influenza A Virus in an Endocytic Pathway Enhances Viral Replication J. Virol., September 15, 2005; 79(18): 11705 - 11715. [Abstract] [Full Text] [PDF]

				S. J. F. Macdonald, K. G. Watson, R. Cameron, D. K. Chalmers, D. A. Demaine, R. J. Fenton, D. Gower, J. N. Hamblin, S. Hamilton, G. J. Hart, et al. Potent and Long-Acting Dimeric Inhibitors of Influenza Virus Neuraminidase Are Effective at a Once-Weekly Dosing Regimen Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4542 - 4549. [Abstract] [Full Text] [PDF]

				P. Bonnet and R. A. Bryce Molecular dynamics and free energy analysis of neuraminidase-ligand interactions Protein Sci., April 1, 2004; 13(4): 946 - 957. [Abstract] [Full Text] [PDF]

				M. Z. Wang, C. Y. Tai, and D. B. Mendel Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir Antimicrob. Agents Chemother., December 1, 2002; 46(12): 3809 - 3816. [Abstract] [Full Text] [PDF]

				A. Molla, W. Kati, R. Carrick, K. Steffy, Y. Shi, D. Montgomery, N. Gusick, V. S. Stoll, K. D. Stewart, T. I. Ng, et al. In Vitro Selection and Characterization of Influenza A (A/N9) Virus Variants Resistant to a Novel Neuraminidase Inhibitor, A-315675 J. Virol., May 3, 2002; 76(11): 5380 - 5386. [Abstract] [Full Text] [PDF]

				L. V. Gubareva, R. G. Webster, and F. G. Hayden Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3403 - 3408. [Abstract] [Full Text] [PDF]

				B. J. Smith, P. M. Colman, M. Von Itzstein, B. Danylec, and J. N. Varghese Analysis of inhibitor binding in influenza virus neuraminidase Protein Sci., April 1, 2001; 10(4): 689 - 696. [Abstract] [Full Text]

				J. N. Varghese, P. M. Colman, A. van Donkelaar, T. J. Blick, A. Sahasrabudhe, and J. L. McKimm-Breschkin Structural evidence for a second sialic acid binding site in avian influenza virus neuraminidases PNAS, October 28, 1997; 94(22): 11808 - 11812. [Abstract] [Full Text] [PDF]